Search results
Results from the WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...
Health care firm Roche announced in a press release Thursday that the FDA has approved a new indication for its cancer drug Avastin. The new usage will allow Roche to market Avastin, in ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Roche's (RHHBY) blockbuster cancer drug, Avastin, is up for review by the U.S. Food and Drug Administration next month. If the FDA follows its advisory panel's recommendation from last month, it ...
Pfizer's Zirabev received approval for the treatment of five types of cancer, including colorectal and lung cancers, it said. In 2017, U.S.-based Amgen Inc's Mvasi was approved by the FDA as the ...
Currently, there are two FDA approved antibody therapies for Alzheimer's disease, Aducanemab and Lecanemab. Aducanemab has received accelerated approval while Lecanemab has received full approval. [25] Several clinical trials using passive and active immunization have been performed and some are on the way with expected results in a couple of ...
Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF) in the circulation and functions as an angiogenesis inhibitor. [16] The main treatment arms of phase 3 clinical trials providing immunotherapy in the first line for patients with non-small cell lung cancer.